Itrapoint 200 Capsule contains Itraconazole 200 mg, a broad-spectrum antifungal agent belonging to the triazole class. It is indicated for the treatment of various systemic and superficial fungal infections caused by susceptible fungi, including aspergillosis, blastomycosis, histoplasmosis, and onychomycosis. Itraconazole exerts its antifungal effect by inhibiting the cytochrome P450-dependent enzyme lanosterol 14-α-demethylase, which is essential for the conversion of lanosterol to ergosterol, a critical component of fungal cell membranes. This disruption leads to increased membrane permeability and ultimately fungal cell death. Itrapoint 200 Capsule is administered orally and should be taken with food to enhance absorption. The dosage and duration of therapy depend on the type and severity of the infection, and treatment should be guided by clinical response and susceptibility testing where available. Caution is advised in patients with hepatic impairment, congestive heart failure, or those taking concomitant medications metabolized via the cytochrome P450 system due to potential drug interactions. Common adverse effects include gastrointestinal disturbances, headache, and rash. Regular monitoring of liver function tests is recommended during prolonged therapy. Itrapoint 200 Capsule should be used under medical supervision to ensure safe and effective antifungal treatment.